Omnicell, Inc. $OMCL Holdings Decreased by Deutsche Bank AG

Key Points

• Deutsche Bank AG reduced its stake in Omnicell, Inc. by 20.3% during the first quarter, owning approximately $1.46 million worth of shares after the sale of 10,658 shares.
• Omnicell reported earnings per share of $0.45 for the last quarter, exceeding analysts' estimates by $0.15, alongside a revenue of $290.56 million, reflecting a 5% year-over-year growth.
• Various analysts have adjusted their price targets for Omnicell, with a consensus rating of "Moderate Buy" and an average price target of $46.71.

Deutsche Bank AG lowered its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 20.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,835 shares of the company's stock after selling 10,658 shares during the quarter. Deutsche Bank AG owned about 0.09% of Omnicell worth $1,463,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Johnson Financial Group Inc. bought a new stake in shares of Omnicell during the 4th quarter worth about $37,000. Point72 Hong Kong Ltd bought a new position in shares of Omnicell in the fourth quarter valued at approximately $101,000. Corton Capital Inc. acquired a new position in shares of Omnicell during the fourth quarter valued at approximately $208,000. Caption Management LLC bought a new stake in Omnicell during the fourth quarter worth approximately $223,000. Finally, New Age Alpha Advisors LLC bought a new stake in Omnicell during the first quarter worth approximately $233,000. Institutional investors own 97.70% of the company's stock.

Omnicell Trading Up 5.4%

NASDAQ:OMCL opened at $33.62 on Friday. The stock has a fifty day simple moving average of $29.62 and a 200 day simple moving average of $31.92. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of 67.24, a price-to-earnings-growth ratio of 9.31 and a beta of 0.78. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.74. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. During the same period in the prior year, the firm earned $0.51 earnings per share. The business's quarterly revenue was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Sell-side analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Wall Street Analyst Weigh In

OMCL has been the subject of a number of research reports. Benchmark decreased their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Bank of America raised their target price on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Wells Fargo & Company lifted their target price on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Piper Sandler dropped their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 11th. Finally, Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.